| Similar Articles |
|---|
 |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here?   |
The Motley Fool
July 29, 2011
Sean Williams |
Another Day, Another Loss For Cell Therapeutics Cell Therapeutics is giving shareholders that sinking feeling. |
The Motley Fool
July 1, 2011
Brian Orelli |
What Will Cell Therapeutics Do With Your Money? Unfortunately the answer is probably, "buying a drug." |
The Motley Fool
June 15, 2011
Brian Orelli |
Investors Need a Peephole Into FDA Offices Cell Therapeutics is gung ho about its resubmission, but investors only get one side of the story. |
The Motley Fool
July 20, 2010
Jordan DiPietro |
Cell Therapeutics Finds a New Home The company signs a long-term agreement with an Italian manufacturer for a lymphoma treatment. |
The Motley Fool
June 15, 2005
Brian Gorman |
Cell Therapeutics' Gamble The biotech company's struggles are far from over. Without an approved drug on the market or the certainty of FDA clearance, the firm won't have an easy time finding investors. |
The Motley Fool
May 27, 2011
Brian Orelli |
What Kind of Phase 2 Drug Can You Get for $5 Million? Cell Therapeutics issues a press release saying the company has identified a potential acquisition opportunity that is a phase II drug candidate. |
The Motley Fool
October 14, 2010
Matt Koppenheffer |
Cell Therapeutics' Shares Popped: What You Need to Know Shares of biopharma specialist Cell Therapeutics leapt more than 16% today on huge volume. |
The Motley Fool
September 28, 2011
Brian Orelli |
One Step Closer to an FDA Decision Cell Therapeutics is still risky, though. |
The Motley Fool
April 7, 2009 |
Today's 5-Star Movers A list of today's top moving stocks from the Motley Fool five-star stock list. |
The Motley Fool
September 15, 2010
Brian Orelli |
Cell Therapeutics Goes for Broke If Cell Therapeutics can't get new funding soon, long-term consequences may be the least of its worries; time on the clock looks to be running out. |
The Motley Fool
October 19, 2010
Travis Hoium |
Cell Therapeutics Shares Popped: What You Need to Know Cell Therapeutics shares jumped 11% today on news the company received a positive opinion for Pixuvri. |
The Motley Fool
September 17, 2010
Luke Timmerman |
Cell Therapeutics OK'd to Sell Shares to Stay Alive Is the company being straight with shareholders? |
BusinessWeek
September 29, 2003
Gene G. Marcial |
Taking Aim at Cancer Cell Therapeutics isn't expected to make money until 2007, but Edward Hemmelgarn, president of Shaker Investments, is buying into the small-cap biotech anyway. Shaker already owns 1.7 million shares. Cell is developing cancer treatments that are less toxic but more effective, he says. |
The Motley Fool
November 1, 2006
John Reeves |
7 More Surprising 1-Star Stocks Can these stocks keep up the momentum? New River Pharmaceuticals... Acorda Therapeutics... NVE... American Power Conversion... etc. |
The Motley Fool
March 12, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend by hitting new highs. Take a look at: CV Therapeutics... AutoZone... |
The Motley Fool
October 12, 2005
W.D. Crotty |
Nokia's New Family of Phones A new line of keyboard-armed cell phones aims for business users. Nokia will benefit from trends like this that it can ride to sales glory, but investors should consider the opportunities that Internet-enabled phones provide for e-mail and other providers. |
The Motley Fool
December 9, 2011
David Williamson |
1 Biotech Soars While Another Crashes Cell Therapeutics dilutes shareholders while SIGA squashes fears. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
The Motley Fool
June 11, 2009 |
Today's 5-Star Movers A list of today's top-moving stocks from the Motley Fool five-star stock list. |
The Motley Fool
April 4, 2005
John Reeves |
Returns That Defy the Imagination Want to save lives while pursuing a high-growth investment strategy? Try exploring the biotech frontier. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
The Motley Fool
July 13, 2011
David Williamson |
Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of. |
The Motley Fool
August 6, 2007
Andrew R. Vaino |
NPS Pharmaceuticals: What's for Dinner? The small biotech pins its hopes on a drug that helps patients digest their food. Because the company's market cap is just $180 million, shares could jump significantly on a positive clinical result. |
The Motley Fool
January 23, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Geron... American Science & Engineering... |
The Motley Fool
November 18, 2010
Travis Hoium |
Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam. |
The Motley Fool
August 31, 2009 |
2 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs. Take a look at: Marvel Entertainment... Sinovac Biotech... |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
The Motley Fool
April 7, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: United States Natural Gas Fund... Arena Pharmaceuticals... |
The Motley Fool
February 9, 2009 |
2 Stocks Hitting High Notes These stocks are bucking the trend and hitting new highs. Take a look at: Myriad Genetics... Hot Topic... |
The Motley Fool
January 4, 2012
Brian Orelli |
Mark Your Calendars, Biotech Investors Cell Therapeutics' advisory panel meet ought to be entertaining. |
The Motley Fool
August 18, 2010
Charly Travers & Seth Jayson |
Will United Therapeutics Burn You? United Therapeutics is cash flow-positive and has mostly been over the past few years. That's investment nirvana for biotech shareholders. This is a rare beast worthy of additional research. |
The Motley Fool
May 18, 2004
Selena Maranjian |
Places for Great Investment Ideas There are some good investment newsletters out there, even from us. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
August 26, 2009 |
3 Stocks Hitting High Notes These stocks are reaching for the stars and hitting 52-week highs. Take a look at: Bed Bath & Beyond... Sinovac Biotech... Dollar Tree Stores... |
The Motley Fool
November 6, 2009 |
3 Stocks Hitting High Notes These stocks are hitting 52-week highs: Randgold Resources... Vertex Pharmaceuticals... T-3 Energy Services... |
Chemistry World
May 7, 2013
Phillip Broadwith |
AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
Chemistry World
January 26, 2015
Phillip Broadwith |
Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion. |
The Motley Fool
August 3, 2009 |
2 Stocks Hitting Low Notes UltraShort Real Estate ProShares and Genzyme have gone lower. Are they ready to bounce? |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
The Motley Fool
June 16, 2010
Rex Moore |
Tiny Company, Tons of Cash These micro-cap companies may have an advantage when the economy turns. |
The Motley Fool
February 19, 2009 |
2 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: BioMarin Pharmaceutical... National Instruments Corp... |
The Motley Fool
February 27, 2009 |
3 Stocks Hitting Low Notes These stocks have hit bottom. Are they ready to bounce? Take a look at: Fortune Brands... Martek Biosciences... EZCORP... |
The Motley Fool
July 27, 2010
Brian Orelli |
Better Buy: Cell Therapeutics or Sequenom? Which one deserves your dollars more? |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
January 4, 2007
Ralph Casale |
Picks and Shovels of Biotechnology Biotech investors will continue to venture into the dark mines of burgeoning pharmaceutical firms. There is certainly gold to be found in some of them, just remember to invest in some of the hardware stores of biotechnology along the way. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
October 26, 2009
Adam J. Wiederman |
Time to Sell and Lock in Your Gains With stocks up so much, it might be time to take some money off the table. |
The Motley Fool
August 11, 2009 |
3 Stocks Hitting High Notes Tellabs... Human Genome Sciences... priceline.com... etc. |
